Meeting News CoverageVideo

VIDEO: Speaker discusses practical issues of melanoma molecular testing

NEW YORK — Jane L. Messina, MD, an anatomic pathologist of the Melanoma Research Center of Excellence at Moffitt Cancer Center, discussed practical issues associated with molecular testing for the diagnosis and prognostication of melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

In particular, she reviewed how cost, sensitivity/specificity and the amount of necessary biopsied tissue vary for use of fluorescence in situ hybridization, comparative genomic hybridization, gene expression profiling, melanoma-specific mutation screening and next-generation sequencing.

“There is really a great need to get the results of all of the clinical trials where patient tumors were submitted and are presumably being analyzed so that we can come up with a panel to effectively target patients who are going to receive the most benefit from those drugs,” Messina said.

NEW YORK — Jane L. Messina, MD, an anatomic pathologist of the Melanoma Research Center of Excellence at Moffitt Cancer Center, discussed practical issues associated with molecular testing for the diagnosis and prognostication of melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

In particular, she reviewed how cost, sensitivity/specificity and the amount of necessary biopsied tissue vary for use of fluorescence in situ hybridization, comparative genomic hybridization, gene expression profiling, melanoma-specific mutation screening and next-generation sequencing.

“There is really a great need to get the results of all of the clinical trials where patient tumors were submitted and are presumably being analyzed so that we can come up with a panel to effectively target patients who are going to receive the most benefit from those drugs,” Messina said.

    See more from HemOnc Today New York